Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Engineering genetic circuits for epigenetic control of transgene expression in T-cell therapies

FY 2025-26

Summary
A significant challenge in developing long-lasting cell therapies, such as engineered T cells used to fight cancer, is that added treatment genes can gradually weaken or be switched off as cells grow, divide, and adapt to their environment. This loss of activity occurs naturally over time as cells change their identity or respond to stress. When the treatment gene is no longer fully active, the therapy becomes less effective and may not provide a lasting benefit. This project aims to build a genetic support system that keeps the treatment gene active as the cell develops. Current approaches often rely on fixed genetic components to maintain gene activity, but these tools cannot adjust when the cell naturally begins to turn off the gene. In contrast, we will design a cooperative set of “sentinel” helpers that will operate as a network to provide ongoing support to help keep the gene active as cells develop and respond to their environment. This sentinel system is a new approach we are proposing, intended to operate more dynamically than existing strategies and may help maintain gene activity more reliably over time. We will first build and test several versions of this sentinel system in lab-grown cells to find the most reliable design. Then we will assess whether it protects gene expression in engineered human T cells. Finally, we will apply the most robust designs during the process of turning stem cells into T cells, which is an emerging method for generating therapy-ready immune cells. If successful, this approach could help make engineered cell therapies more reliable and longer lasting. It may also advance the design of future genetic treatments by showing how to protect key therapeutic genes as cells change over time.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572735
Name
Ellis Darian
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering genetic circuits for epigenetic control of transgene expression in T-cell therapies
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Chromatin Accessibility; Crispr Epigenetic Modulation; Dcas9-Based Activation; Gene Therapy; Genetic Engineering; Histone Acetylation; Stem Cell-Derived Immunotherapy; Synthetic Gene Circuits; T-Cell Differentiation; Transgene Silencing
Abstract
A significant challenge in developing long-lasting cell therapies, such as engineered T cells used to fight cancer, is that added treatment genes can gradually weaken or be switched off as cells grow, divide, and adapt to their environment. This loss of activity occurs naturally over time as cells change their identity or respond to stress. When the treatment gene is no longer fully active, the therapy becomes less effective and may not provide a lasting benefit. This project aims to build a genetic support system that keeps the treatment gene active as the cell develops. Current approaches often rely on fixed genetic components to maintain gene activity, but these tools cannot adjust when the cell naturally begins to turn off the gene. In contrast, we will design a cooperative set of “sentinel” helpers that will operate as a network to provide ongoing support to help keep the gene active as cells develop and respond to their environment. This sentinel system is a new approach we are proposing, intended to operate more dynamically than existing strategies and may help maintain gene activity more reliably over time. We will first build and test several versions of this sentinel system in lab-grown cells to find the most reliable design. Then we will assess whether it protects gene expression in engineered human T cells. Finally, we will apply the most robust designs during the process of turning stem cells into T cells, which is an emerging method for generating therapy-ready immune cells. If successful, this approach could help make engineered cell therapies more reliable and longer lasting. It may also advance the design of future genetic treatments by showing how to protect key therapeutic genes as cells change over time.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ellis, Darian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~